Content Currently Unavailable
Why Early QC Planning Matters in Cell and Gene Therapy
Late-stage CMC setbacks often begin with early QC decisions that shape cell and gene therapy timelines, costs, and regulatory outcomes
Content Currently Unavailable
False
Advertisement
Related Content
Cell & Gene
Power List
Development & Clinical
Musings from The Power List: John Maher
August 14, 2026
4 min read
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
Cell & Gene
Development & Clinical
Interviews
Why Cell Therapy Needs a Digital Backbone
August 13, 2026
8 min read
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
Development & Clinical
Future of Pharma
Technology & Manufacturing
What Did ASCO 2026 Reveal About the Future of Oncology?
August 6, 2026
8 min read
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
Development & Clinical
Biopharma
Interviews
How China Is Rewriting the Rules Global Drug Development
August 5, 2026
14 min read
In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development